Nitrase Therapeutics: Funding, Investors & Team (Oct 2026)
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
Nitrase Therapeutics has raised $7.0M across 1 funding round on record, the most recent a Series A of $7.0M announced in Nov 2021.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nitrase Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2021.
Nitrase Therapeutics Funding Rounds
Nitrase Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Nitrase Therapeutics Funding Compared to Other Biotechnology Startups
Nitrase Therapeutics' latest round of $7.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nitrase Therapeutics in Biotechnology and Jackson
Companies Similar to Nitrase Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Nitrase Therapeutics Funding FAQs
What does Nitrase Therapeutics do?
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
How much funding has Nitrase Therapeutics raised?
Nitrase Therapeutics has raised $7.0M across 1 round on record. The most recent is a Series A of $7.0M announced in Nov 2021.
When did Nitrase Therapeutics last raise funding?
Nitrase Therapeutics' most recent funding round on record is a Series A of $7.0M, announced in Nov 2021.
Who is the CEO of Nitrase Therapeutics?
Pierre Beaurang is listed as CEO at Nitrase Therapeutics.
Where is Nitrase Therapeutics headquartered?
Nitrase Therapeutics is based in Jackson, Mississippi, United States.
How many employees does Nitrase Therapeutics have?
Nitrase Therapeutics is in the 11-50 employee band.
How does Nitrase Therapeutics' funding compare to other Biotechnology startups?
Nitrase Therapeutics' latest round of $7.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Nitrase Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nitrase Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.